Lixa
Lixa is an Australian clinical-stage biotech developing NeoX™, a proprietary class of universal antimicrobial resistance breakers (uARBs) that restore the effectiveness of existing antibiotics across human health, marine, industrial, and agribusiness applications.
- Company typePrivate
- Founded2021
- HeadquartersPerth, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lixa does
Lixa is an Australian clinical-stage biotechnology company developing the NeoX™ platform, a proprietary class of small molecules termed universal antimicrobial resistance breakers (uARBs). These molecules are designed to reroute the metabolic pathways that fuel bacterial resistance, effectively switching pathogens from a resistant to a sensitive state so that existing antibiotics, biocides, and antimicrobial treatments regain efficacy rather than relying on the traditional cycle of developing ever-stronger antibiotics. The platform is positioned as a novel treatment category with demonstrated lab efficacy of 100–10,000x enhanced kill against multidrug-resistant organisms (E. coli, K. pneumoniae, P. aeruginosa, MRSA), >90% biofilm mass reduction in priority pathogens, and no resistance development observed against NeoX itself after 30 days of exposure.
Lixa's product pipeline centres on two drug candidates: NeoX-101, an inhaled formulation that has completed Phase 1 clinical trials with safety and tolerability confirmed across all dose levels (with lab data also supporting oral and IV formulations), and NeoX-121, which is being advanced into clinical trials for antimicrobial resistance in partnership with the Global Antibiotic Research & Development Partnership (GARDP). Beyond pharmaceutical applications, the platform is being developed for marine/shipping antifoul technologies, industrial bioprocesses, consumer products, and agricultural systems, addressing the same underlying resistance mechanisms that drive biofilm fouling and agricultural system instability.
Commercially, Lixa pursues a dual-track business model: (i) in-house development of drug candidates through clinical and regulatory pathways for eventual out-licensing or product commercialisation, and (ii) a multi-vertical technology-licensing strategy offering the NeoX platform to pharmaceutical, industrial, food, FMCG, and agribusiness partners for integration or co-development. The company, founded in 2021 and headquartered in Nedlands (Perth), Western Australia, had raised approximately AU$30 million in disclosed funding through its 2024 Series B round at the time of input, with no commercial product revenue yet disclosed.
Lixa firmographics
Firmographics- Name
- Lixa
- Legal name
- Lixa Ltd
- Website
- https://lixa.life
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lixa is an Australian clinical-stage biotech developing NeoX™, a proprietary class of universal antimicrobial resistance breakers (uARBs) that restore the effectiveness of existing antibiotics across human health, marine, industrial, and agribusiness applications.
- Ownership category
- akta.pro rank
Lixa industry classification
Industry- Product category
- Antimicrobial Resistance Drug Development
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Custom Intermediates & Advanced Intermediates Manufacturing (HLAGAHAH)
Keywords
Where Lixa is headquartered
LocationHeadquarters
- HQ city
- Perth
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Lixa business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Technology Licensing: NeoX™ platform is designed for multiple licensing pathways across compounding markets including human health (pharmaceuticals), marine/shipping (antifoul technologies), industrial bioprocesses, consumer products, and agribusiness. The company seeks strategic partners for integration, licence or co-development.
- Drug Development & Clinical Advancement: Lixa advances its own drug candidates (e.g. Neox-121) into clinical trials, either independently or in partnership with global health organisations. Revenue would ultimately come from pharmaceutical product sales or licensing upon regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Lixa product offering
Product offeringCore offering
Lixa develops the proprietary NeoX™ platform, a class of small molecules called universal antimicrobial resistance breakers (uARBs) that switch bacteria from resistant to sensitive states by rerouting metabolic pathways. The company advances drug candidates NeoX-101 (inhaled, Phase 1 complete) and NeoX-121 (advancing to clinical trials) and licenses the platform across human health, marine/shipping, industrial systems, consumer products, and agribusiness.
Product overview
Lixa is a pharmaceutical biotechnology company developing the NeoX™ platform, a proprietary class of small molecules called universal antimicrobial resistance breakers (uARBs). The platform includes two drug candidates: NeoX-101 (inhaled formulation with completed Phase 1 trials) and NeoX-121 (advancing to clinical trials). NeoX™ technology addresses AMR by switching off bacterial resistance mechanisms, restoring effectiveness of existing antibiotics rather than developing new ones. The platform is designed for deployment across infection types, species, and industries including human health, marine, industrial, and agricultural systems.
Differentiator
Problem solved
Functional benefit
Brands
- NeoX: A class of small molecules called universal antimicrobial resistance breakers (uARBs) that switch bacteria from resistant to sensitive states
- NeoX-101
- NeoX-121
Products and services
- NeoX-101 Inhaled formulation of Lixa's NeoX uARB drug candidate that completed Phase 1 clinical trials, where it was found to be safe and very well tolerated at all doses tested. Lab data confirms similar safety for oral and IV formulations, supporting development across multiple delivery routes for treating multidrug-resistant infections.
- NeoX-121 Lixa's lead drug candidate being advanced to clinical trials for antimicrobial resistance (AMR). Part of the NeoX platform, it works by switching bacteria from a resistant to a sensitive state to restore effectiveness of existing antibiotics.
Quantifiable outcome
- 100–10,000x enhanced kill effect against multidrug-resistant bacteria including E. coli, K. pneumoniae, P. aeruginosa and MRSA
- +3 more outcomes
Companies that use Lixa
Customer profileSegments2 records
Ideal customer profiles4 records
Lixa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Lixa partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Global Antibiotic Research & Development Partnership (GARDP)coreLixa has partnered with the Global Antibiotic Research & Development Partnership (GARDP) to advance Neox-121 to clinical trials for antimicrobial resistance. This partnership combines Lixa's proprietary NeoX resistance-breaking technology with GARDP's global health mission and R&D network to address the growing global AMR threat. The collaboration aligns with global Access, regulatory and stewardship priorities.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Lixa competitors and assessment
Company assessmentDirect peers
- VenatoRx Pharmaceuticals: Clinical-stage antibiotic developer focused on multidrug-resistant Gram-negative infections, directly competing in the AMR therapeutics space with novel mechanisms targeting resistance. Comparable in stage, mechanism novelty, and target pathogens.
- Iterum Therapeutics: Clinical-stage company developing oral and IV antibiotics against multidrug-resistant pathogens including resistant E. coli and Klebsiella. Direct competitor in AMR space with overlapping pathogen focus (E. coli, K. pneumoniae) targeted by NeoX.
- Melinta Therapeutics: Antibiotic-focused company developing therapies for serious and drug-resistant bacterial infections. Comparable product category (anti-infectives targeting resistant pathogens) and comparable regulatory pathway, though Melinta emerged from bankruptcy restructuring.
- Paratek Pharmaceuticals: Commercial-stage developer of antibiotics for serious community-acquired infections including resistant pathogens. Comparable in addressing resistant bacterial infections, with an approved tetracycline-class product (Nuzyra).
- Cidara Therapeutics: Clinical-stage anti-infective company developing novel antivirulence and antifungal approaches, including immune-focused conjugates. Comparable as a developer of novel-mechanism anti-infectives targeting resistance and treatment failure.
- Tetraphase Pharmaceuticals: Developed Xerava (eravacycline) for complicated intra-abdominal infections caused by resistant bacteria. Historical direct peer in AMR antibiotic space (acquired by La Jolla Pharmaceutical Company in 2023), illustrating the consolidation pattern in AMR biotech.
Emerging players
- Microbion Corporation: Clinical-stage company developing MBN-101 and related compounds to disrupt bacterial biofilms for chronic and resistant infections. Direct overlap with Lixa's biofilm disruption capability, particularly relevant for chronic wound and orthopedic indications.
- Seres Therapeutics: Clinical-stage microbiome therapeutics company developing treatments for recurrent C. difficile and other resistant bacterial infections. Comparable in targeting resistant and recurrent bacterial infections but with a fundamentally different (microbiome-based) mechanism.
- Kane Biotech: Canadian biotech developing biofilm-disrupting therapies and wound care products targeting resistant bacterial biofilms. Direct overlap with Lixa's biofilm disruption thesis, particularly in consumer and animal health applications.
Others
- Achaogen: Historical direct peer (now defunct/bankrupt in 2019) that developed plazomicin for drug-resistant Gram-negative infections. Cited as a cautionary historical peer illustrating the commercial failure pattern in AMR biotech despite regulatory approval.
Market position
Strengths5 records
Weaknesses1 record
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Lixa social profiles
Digital presenceLixa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lixa leadership team
Management profileNumber of profiles
Profiles17 records
Lixa funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lixa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lixa
What does Lixa do?
Lixa develops the proprietary NeoX™ platform, a class of small molecules called universal antimicrobial resistance breakers (uARBs) that switch bacteria from resistant to sensitive states by rerouting metabolic pathways. The company advances drug candidates NeoX-101 (inhaled, Phase 1 complete) and NeoX-121 (advancing to clinical trials) and licenses the platform across human health, marine/shipping, industrial systems, consumer products, and agribusiness.
Is Lixa a public or private company?
Lixa is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lixa founded?
Lixa was founded in 2021. It employs 1 to 10 people.
Where is Lixa based?
Lixa is headquartered in Perth, Australia, in the Oceania region.
How does Lixa make money?
Two revenue lines are on record. Technology Licensing is the primary driver. The others are drug Development & Clinical Advancement.
Who are Lixa's main competitors?
Direct peers on record are VenatoRx Pharmaceuticals, Iterum Therapeutics, Melinta Therapeutics, Paratek Pharmaceuticals, Cidara Therapeutics and Tetraphase Pharmaceuticals. Emerging players are Microbion Corporation, Seres Therapeutics and Kane Biotech. Achaogen is listed as an others.
Does Lixa have an API?
No public API is recorded for Lixa.
What industry is Lixa in?
Lixa's product category is Antimicrobial Resistance Drug Development. Its primary akta.pro industry code is HLAGAHAH, Custom Intermediates & Advanced Intermediates Manufacturing. Its NAICS code is 32541 and its SIC code is 2834.